miR-219-3p regulates the occurrence of hepatic fibrosis by targeting Smad2

Area of Science:

• Molecular Biology
• Hepatology
• Biochemistry

Background:

• Abnormal microRNA (miR)-219-3p expression is implicated in various cancers.
• The role of miR-219-3p in hepatic fibrosis (HF) progression remains unexplored.

Purpose of the Study:

• To investigate the involvement of miR-219-3p in hepatic fibrosis.
• To explore miR-219-3p as a potential biomarker and therapeutic target for HF.

Main Methods:

• Quantification of miR-219-3p levels in peripheral blood and liver tissues using reverse transcription quantitative polymerase chain reaction.
• Receiver operating characteristic (ROC) curve analysis for diagnostic potential.
• In vitro studies involving hepatic stellate cells transfected with miR-219-3p mimics.
• Western blot analysis to assess protein expression.
• Target gene identification and validation.

Main Results:

• miR-219-3p levels were significantly decreased in HF patients and fibrotic liver tissues compared to controls.
• ROC curve analysis suggested miR-219-3p's potential for HF screening.
• Overexpression of miR-219-3p suppressed key fibrotic markers including Snai1, VE-cadherin, Vimentin, TGF-β1, and GFAP at both mRNA and protein levels.
• Smad2 was identified as a direct target of miR-219-3p.
• Silencing Smad2 counteracted the inhibitory effects of miR-219-3p on TGF-β1 signaling.

Conclusions:

• Reduced miR-219-3p in peripheral blood may serve as a biomarker for hepatic fibrosis.
• miR-219-3p plays a protective role in hepatic fibrosis by targeting Smad2 and inhibiting TGF-β1 signaling.
• miR-219-3p represents a potential therapeutic target for managing hepatic fibrosis progression.